Preliminary study results presented at the 2026 Military Health System Research Symposium (MHSRS) show reductions in evacuation and surgical treatment times in combat medical settings. MEDIA, Pa., Sept. 29, 2026 /PRNewswire-PRWeb/ -- InfraScan, Inc., a medical device company specializing in portable brain injury assessment technology, announced the completion of the…
Read More
TLB-33 adds a complementary mechanism and further expands Tolerance Bio’s clinical-stage pipeline targeting thymic biology Company planning Phase 2 clinical development beginning in 2027 as it builds a pipeline of complementary modalities to improve thymic function for better healthspan PHILADELPHIA, P.A. – September 28, 2026 - Tolerance Bio, Inc. (“Tolerance Bio” or…
Read More
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) and Atalan today announced a new research collaboration focused on advancing understanding of the factors that influence physician retention across U.S. health systems. The two organizations have agreed to combine resources and launch the PROGRESS Study (Physician Retention,…
Read More
HOUSTON, Sept. 9, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announces the appointment of Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors. Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and…
Read More
Bristol Myers Squibb and seasoned biotechnology veteran Donald Hayden, M.B.A., appointed as Chairman of the Latus Board of Directors Former Chief Financial Officer of Avidity Biosciences Michael MacLean appointed as independent director and Chair of the Audit Committee Appointments come as Latus advances its lead programs into clinical trials, including…
Read More
For much of the last decade, healthcare AI has been evaluated like a technology story. Investors focused on model performance. Founders competed on accuracy. Health systems asked whether an algorithm could outperform existing workflows. Those factors still matter. But they are becoming less differentiating. Open-source models, foundation models, and increasingly…
Read More
Company preparing to advance efineptakin alfa into Phase 2 studies to evaluate enhancement of thymic function and improve immune resilience Clinical experience with IL-7 in immunologically vulnerable populations, including in people living with cancer or HIV, supports its potential to address impaired immune reconstitution PHILADELPHIA--(BUSINESS WIRE)--Tolerance Bio, Inc. (“Tolerance Bio”…
Read More
Highlights New Investments, Exits, and Portfolio Progress Across the Mid-Atlantic Philadelphia, PA – August 4, 2026 – In the 18 months ended June 2026 (covering the period from January 1, 2025, to June 30, 2026), BioAdvance Capital continued to support the next generation of life sciences innovation across the Mid-Atlantic,…
Read More
Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics· ARPA-H PROSPR Program
Melior Discovery will conduct preclinical in vivo pharmacology studies supporting Linnaeus' ARPA-H PROSPR-funded development of LNS880l for healthspan preservation EXTON, Pa., July 21, 2026 /PRNewswire-PRWeb/ -- Melior Discovery, Inc. (Melior), a dedicated in vivo pharmacology contract research organization (CRO) with deep expertise in phenotypic screening and preclinical model development, today…
Read More
The Coalition and American Hospital Association, AdventHealth, Atalan, and Providence’s Well Being Trust collaborate on practical framework for healthcare initiative evaluation ALTAMONTE SPRINGS, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- The Coalition for Physician & APP Well-Being, a non-profit entity comprised of national healthcare organizations dedicated to fostering the well-being…
Read More
PHILADELPHIA, June 25, 2026 (GLOBE NEWSWIRE) -- Nurse burnout remains a significant challenge in the healthcare industry, with growing interest in tools that can help identify retention risk earlier. Atalan for Nursing is intended to address this need. Atalan, the leading Clinician Retention Intelligence (CRI) platform, today announced the launch…
Read More
BCI’s second investment to advance therapeutic treatments for celiac disease will support preclinical development of novel approach to immune tolerance AMBLER, PA, UNITED STATES, June 22, 2026 /EINPresswire.com/ -- Beyond Celiac Investments (BCI), the venture philanthropy program of Beyond Celiac, today announced an investment in Tolerance Bio Inc., to support…
Read More
Established biopharmaceutical executive with more than 25 years of business development, corporate strategy, financing, and transaction experience Demonstrated leader in gene therapy and CNS drug development Appointment comes as Latus enters the clinic, with LTS-201 for Huntington’s disease on track for IND submission in 3Q 2026 PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus…
Read More
Elsevier's ClinicalKey Al and Wei/sheet will deliver verifiable clinical evidence and patient context directly into the EHR, giving clinicians governed Al answers within their existing workflows NEW YORK, June 3, 2026 /PRNewswire/ -- Elsevier today announced it has acquired Wellsheet, a US-based health technology company that specializes in aggregating and…
Read More
lmmuno-oncology leader brings more than three decades of experience advancing innovative cancer therapies across biotech, pharma, and the National Cancer Institute HOUSTON, May 28, 2026 /PRNewswire/ -- lmmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr…
Read More
Two appointments add drug development and defense-sector expertise to Ladder Bio’s Board as the company advances its Spiroligomer™ platform BLUE BELL, Pa.--(BUSINESS WIRE)--Ladder Bio, Inc., a structure-guided biotechnology company developing Spiroligomers™, a new class of chemical matter as medicines, today announced the appointments of Jay Fine, PhD, and John Prufeta…
Read More
Financing extension led by 8VC to advance LTS-201 as a potential significant commercial opportunity in Huntington’s disease (IND expected in 3Q 2026) Potential clinical proof-of-concept of Latus platform from LTS-101 in CLN2 disease expected in 4Q 2026; multiple fast follow-ons utilize the same capsid for larger indications Proprietary engineered AAV…
Read More
Computational and preclinical data support advancement of LTS-201 and LTS-101 programs into clinic later this year Latus founder Beverly Davidson, Ph.D., awarded the ASGCT Outstanding Achievement Award – the Society’s highest honor PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a company advancing scalable genetic medicines for broad patient populations, today…
Read More
The Economic Times, US Story by Maitreyee Thakkar, Global Desk For decades, advances in battlefield medicine have focused on one goal: keep the wounded alive long enough to reach a surgical facility. Tourniquets, hemostatic dressings, rapid evacuation, and forward surgical teams dramatically improved survival in Iraq and Afghanistan. Yet one…
Read More
The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis with proven remote spirometry and FeNO capabilities - creating a unique, single-partner endpoint solution for respiratory sponsors. PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / Strados Labs, the respiratory endpoint intelligence company, today announced the…
Read More